European Research Council Award to Institute Researcher
Eleftheria Zeggini is one of the recipients of Starting Grant awards
A Wellcome Trust Sanger Institute researcher has been recognized in a pan-Europe award scheme for researchers at the early stages of their career. Dr Eleftheria Zeggini was awarded a grant of €1.5 million to support her research into the genetics of common disease in humans.
The European Research Council Starting Grant scheme aims to support up-and-coming research leaders who are about to establish or consolidate a research team to conduct independent research in Europe. Dr Zeggini joined the Wellcome Trust Sanger Institute in November 2008.
Dr Zeggini’s team aims to identify the underlying genetic variants that contribute to human disease and to develop new and more refined tools to help researchers in tackling human disease. They achieve this by carrying out large-scale studies to investigate the genetic architecture of complex traits, with a primary focus on cardiometabolic and musculoskeletal phenotypes. In doing so, they identify and address statistical genetics challenges by designing, evaluating and proposing analytical strategies.
“It’s a great honour to be a recipient of this award, which will boost our research into the genetics of complex human traits.”
Dr Ele Zeggini Group Leader at the Wellcome Trust Sanger Institute
The European Research Council seeks to encourage the highest quality research in Europe through competitive funding and to support investigator-initiated frontier research across all fields of research, on the basis of scientific excellence.
More than 4080 applications were submitted for awards from the €670 million ($900 million) fund provided by the European Research Council: the success rate was 12%.
“I am delighted that Dr Zeggini and her work have been recognized by this grant. It is vital for the future of research that we foster new talent and offer them the opportunities to grow.”
“The European Research Council scheme is an excellent paradigm for European research.”
Professor Mike Stratton Director of the Wellcome Trust Sanger Institute
Dr Zeggini’s proposal to ERC was to conduct a powerful next-generation association study leveraging whole-genome sequence data and the unique characteristics of population isolates, in which rare alleles may have risen in frequency and are thus easier to detect. This work aims to provide the substrate for analytical method development, and, importantly, to identify robust novel associations with complex disease-related traits.
The number of applications increased by 42% in 2011 compared to 2010. The average age of selected researchers was about 37 years and 21% were women. In this latest round, the UK was awarded 124 of the 480 grants. In this call, 35% of applicants were selected in the field of Life Sciences.
If you need help or have any queries, please contact us using the details below.
Notes to Editor
Dr Zeggini obtained her first degree in Biochemistry from the University of Manchester Institute of Science and Technology (UMIST) in 1999 and her PhD in Immunogenetics of Juvenile Arthritis from the arc Epidemiology Unit, University of Manchester, in 2003. After a brief postdoctoral fellowship in Manchester, she joined the Wellcome Trust Centre for Human Genetics, University of Oxford, to work on the genetics of type 2 diabetes. She was awarded a Wellcome Trust Research Career Development Fellowship in 2006 and joined the Wellcome Trust Sanger Institute in November 2008 as a Group Leader, where she heads the Applied Statistical Genetics group.
Set up in 2007 by the EU, the European Research Council is the first pan-European funding organisation for frontier research. It aims to stimulate scientific excellence in Europe by encouraging competition for funding between the very best, creative researchers of any nationality and age. The ERC also strives to attract top researchers from anywhere in the world to come to Europe. It funds both senior research leaders (‘ERC Advanced Grants’) and younger, early-career top researchers(‘ERC Starting Grants’). The substantial funding is awarded based on peer review evaluation and can amount to max. €2 million for a ‘Starting Grant’ and €3.5 million for an ‘Advanced Grant’.
The ERC operates according to an ‘investigator-driven’, or ‘bottom-up’, approach, allowing researchers to identify new opportunities in any field of research. The ERC, which is the newest, pioneering component of the EU’s Seventh Research Framework Programme (‘Ideas’ Specific Programme), has a total budget of €7.5 billion from 2007 to 2013. It is led by the ERC Scientific Council, composed of 22 top scientists and scholars and the ERC President is Prof. Helga Nowotny. The ERC Executive Agency implements the ‘Ideas’ Specific Programme and is lead by Director (adint.) Pablo Amor.
ERC Starting Grant in brief
- For early-career top researchers of any nationality and age, with 2-12 years of experience after
- Funding: up to €2 million per grant for up to 5 years.
- Calls for proposals: published annually in summer with deadlines in autumn.
ERC also supports established research leaders (with significant research achievements in the past ten years). The calls for proposals for ‘Advanced Grants’ are generally published in autumn with deadlines in spring.
The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests.
4 Aug 2020
New podcast to provide digital mentoring tips for early career researchers
Your Digital Mentor launches with first episode on the mentoring experience
30 Jul 2020
New drug targets for lethal brain cancer discovered
Researchers engineered a new mouse model for studying glioblastoma, the most aggressive type of brain cancer